Aceragen, Inc. Stock Nyse
Equities
ACGN
US00445F1093
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | - | Sales 2022 | 4.86M | Capitalization | 3.12M |
---|---|---|---|---|---|
Net income 2021 | 98M | Net income 2022 | -23M | EV / Sales 2021 * | - |
Net cash position 2021 * | - | Net cash position 2022 * | - | EV / Sales 2022 * | - |
P/E ratio 2021 * |
-
| P/E ratio 2022 * |
-
| Employees | 26 |
Yield 2021 * |
-
| Yield 2022 * |
-
| Free-Float | 38.12% |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 43.43B | |
+48.83% | 41.69B | |
+8.49% | 41.31B | |
-10.82% | 27.14B | |
+8.26% | 25.28B | |
-23.69% | 18.47B | |
+1.58% | 12.33B | |
+32.83% | 12.59B | |
+6.63% | 11.03B |